International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, 9054, New Zealand.
Eur J Med Chem. 2020 Aug 15;200:112390. doi: 10.1016/j.ejmech.2020.112390. Epub 2020 May 4.
The mycobacterial membrane protein Large 3 (MmpL3) is an inner membrane protein that transports trehalose-monomycolates, precursors for trehalose-dimycolates and mycolic acids that make up essential components of the mycobacterial outer membrane. Inhibition of MmpL3 weakens the mycobacterial cell wall and ultimately results in cell death in both in vitro and in vivo infection models. This highlights the therapeutic potential of MmpL3 as a drug target. High-throughput whole-cell screening along with whole genome sequencing of resistant mutants has identified numerous classes of compounds that can be classified as MmpL3 inhibitors. In this review, we provide insights into the current development of various MmpL3 inhibitors and discuss the potential challenges in this area.
分枝杆菌膜蛋白 Large 3(MmpL3)是一种内膜蛋白,可运输海藻糖单没食子酸酯、海藻糖二没食子酸酯和分枝菌酸的前体,这些物质构成了分枝杆菌外膜的重要组成部分。MmpL3 的抑制作用削弱了分枝杆菌细胞壁,最终导致体外和体内感染模型中的细胞死亡。这突出了 MmpL3 作为药物靶点的治疗潜力。高通量全细胞筛选以及耐药突变体的全基因组测序已经确定了许多类化合物,这些化合物可以被归类为 MmpL3 抑制剂。在这篇综述中,我们深入探讨了各种 MmpL3 抑制剂的最新发展,并讨论了该领域的潜在挑战。